# Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

> **NCT00546936** · PHASE2 · UNKNOWN · sponsor: **Barnes Retina Institute** · enrollment: 30 (estimated)

## Conditions studied

- Presumed Ocular Histoplasmosis (POHS)

## Interventions

- **DRUG:** ranibizumab
- **DRUG:** verteporfin

## Key facts

- **NCT ID:** NCT00546936
- **Lead sponsor:** Barnes Retina Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2009-10
- **Final completion:** 2010-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546936, "Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00546936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*